A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
Clinical trial NCT02795858 · COMPLETED
Trial details
- NCT number
- NCT02795858
- Sponsor
- Dana-Farber Cancer Institute
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-06-14
- Primary completion
- 2022-12-31
- Enrollment
- 43
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.